Mithu Maheswaranathan, MD
@MithuRheum
Rheumatologist at Duke 🧑🏽💻💉🏥 | Creator of Rheum OnePagers | Infographics • Lupus • Health Literacy | Tweets are my own.
Understanding ANAs, Antinuclear Antibodies — with @AnnKumfer ▶ What does a +ANA mean? ▶ What is the significance of the ANA titer/pattern? ▶ What rheumatic diseases and non-rheumatic diseases are associated with a +ANA? #MedTwitter #Rheumatology #ANA
One thing I hear a lot from fellows (whether going into academics or PP) nationally is they wish fellowship included more training on the business of medicine… Such as billing/coding, RVUs, EHR management & documentation, insurance navigation / prior auths.
Should there be specific training for fellows thinking about going into private practice? Guest J. Thomas Berry, DO, lends his insights HERE → acr.tw/4ntCXfX
🆕 UPDATE: Inebilizumab is now the first FDA approved therapy for IgG4-RD 🚨
🆕 Visual Abstract w/ @HealioRheum 🟢 🔥 New Therapy for IgG4-Related Disease: 📷 RCT of inebilizumab (anti-CD19) vs Placebo in IgG4-RD 👥 Adults with IgG4-RD involving ≥ 2 organs 📷 Results: ⇣ in flare rate + ⇡ complete remission 📷: tinyurl.com/IgG4RDHealio #IgG4RD #RheumX
🆕 PJP Prophylaxis in #Rheumatology 🫁 Created with / Review by @CCalabreseDO 🔹Discuss risk factors for PJP infection 🔹Risk Stratify: CD4 count <200 or ALC <500 = ⇡Risk 🔹Review Treatment options and when to stop PPx? #RheumX #RheumTwitter #PulmTwitter #PJP
💫 Check out the new #RheumMadness x @ RheumOnePagers Bracket Infographic 🏀📟 📚 Read the most innovative #rheum articles (last 2 yrs) 🎧 Check out the Rheum Madness Podcasts 🗳️ Submit your Brackets before April 1, 2025 Collaboration with Rheum Madness Team x @DavidLeverenz
It was an honor to present alongside these two esteemed physician-scientists who have pushed the frontiers of transplantation and cell therapy for patients with autoimmune disorders. #Tandem25 tandemmeetingsnews.com/experts-trace-…
Second edition of Rheumatology Made Ridiculously Simple is out now! This edition we actually have a professional artist and are no longer relying on my own bad drawings! #meded #rheumatology
🚨Apparently all NIH Study Sections have been suspended indefinitely. For those who don’t know, this means there won’t be any review of grants submitted to NIH Depending on how long this goes on for, this could lead to an interruption in billions in research funding.
🎉 #RheumMadness is Back!!! 🎧
🆕 Visual Abstract w/ @HealioRheum 🟢 🔥 New Therapy for IgG4-Related Disease: 📷 RCT of inebilizumab (anti-CD19) vs Placebo in IgG4-RD 👥 Adults with IgG4-RD involving ≥ 2 organs 📷 Results: ⇣ in flare rate + ⇡ complete remission 📷: tinyurl.com/IgG4RDHealio #IgG4RD #RheumX
Report in @NEJM describing the first critically ill adolescent with #H5N1 D1.1 (aka #BirdFlu) in North America. A 13 yo rapidly progressed from mild symptoms to respiratory & renal failure. She survived thanks to IMV + ECMO + CRRT. Scary stuff. 📄 nejm.org/doi/full/10.10…
📑 @NEJM data shows B-cell depletion with @Amgen’s #inebilizumab is effective for #IgG4RD: ⬇️Reduced disease flare rate by 87% ⬆️ Boosted complete remission without extra steroids 🔗bit.ly/3ZTYW66 😶🌫️Foggy on the data? @MithuRheum @RheumOnePagers shares 🔑insights
Happy holidays from the Duke Rheum crew ❄️⛄️🎄 @MithuRheum @DavidLeverenz @CintronDahima @PhilChuMD
Excited to have the opportunity to present on Physician #Burnout in Rheumatology at Grand Rounds today. Thankful many on #RheumTwitter have been voices here on this important topic in our current healthcare climate & trend of physicians exiting clinical medicine!
🔥 Visual Abstract w/ @HealioRheum 🟢 💉 RCT of semaglutide (GLP-1) vs Placebo in OA 🦵 Pts w/ obesity (BMI ≥ 30), knee OA + WOMAC score ≥ 40 ⭐ Results: significantly ⇣ weight and ⇣ pain in semaglutide group (vs PBO) 📝: tinyurl.com/semaglutideOA #Osteoarthritis #RheumX
